A BILL 
To amend the Federal Food, Drug, and Cosmetic Act, with 
respect to eligibility for approval of a subsequent generic 
drug, to remove the barrier to that approval posed by 
the 180-day exclusivity period afforded to a first generic 
applicant that has not yet received final approval, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Bringing Low-cost Op-
4
tions and Competition while Keeping Incentives for New 
5
Generics Act of 2021’’ or the ‘‘BLOCKING Act of 2021’’. 
6
02:46 Jun 08, 2021
H2853
2 
•HR 2853 IH
SEC. 2. CHANGE CONDITIONS OF FIRST GENERIC EXCLU-
1
SIVITY TO SPUR ACCESS AND COMPETITION. 
2
Clause (iv) of section 505(j)(5)(B) of the Federal 
3
Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(B)) 
4
is amended— 
5
(1) in subclause (I), after ‘‘180 days after the 
6
date of the first commercial marketing of the drug 
7
(including the commercial marketing of the listed 
8
drug) by any first applicant’’ by inserting ‘‘or by an 
9
applicant whose application is approved pursuant to 
10
subclause (III)’’; and 
11
(2) by adding at the end the following new sub-
12
clause: 
13
‘‘(III) APPLICANT APPROVAL.—An applica-
14
tion containing a certification described in para-
15
graph (2)(A)(vii)(IV) that is for a drug for 
16
which a first applicant has submitted an appli-
17
cation containing such a certification can be ap-
18
proved notwithstanding the eligibility of a first 
19
applicant for the 180-day exclusivity period de-
20
scribed in subclause (II)(aa) if each of the fol-
21
lowing conditions is met: 
22
‘‘(aa) The approval of such an appli-
23
cation could be made effective, but for the 
24
eligibility of a first applicant for 180-day 
25
exclusivity under this clause. 
26
02:46 Jun 08, 2021
H2853
3 
•HR 2853 IH
‘‘(bb) At least 30 months have passed 
1
since the date of submission of an applica-
2
tion for the drug by at least one first ap-
3
plicant. 
4
‘‘(cc) Approval of an application for 
5
the drug submitted by at least one first ap-
6
plicant is not precluded under clause (iii). 
7
‘‘(dd) No application for the drug 
8
submitted by any first applicant is ap-
9
proved at the time the conditions under 
10
items (aa), (bb), and (cc) are all met, re-
11
gardless of whether such an application is 
12
subsequently approved.’’. 
13
Æ 
02:46 Jun 08, 2021
H2853
